Wechselwirkungen von Metamfetamin

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

CONTRAINDICATIONS Methamphetamine hydrochloride tablets, USP is contraindicated in patients with: known hypersensitivity to amphetamine, or other components of methamphetamine. (Fachinformation zu Metamfetamin, Gegenanzeigen)

CONTRAINDICATIONS Methamphetamine hydrochloride tablets, USP is contraindicated in patients with: known hypersensitivity to amphetamine, or other components of methamphetamine. (Fachinformation zu Metamfetamin, Gegenanzeigen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Excessive Use of Arformoterol Tartrate Inhalation Solution and Use with Other Long-Acting Beta2-Agonists Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Arformoterol, Warnhinweise und Vorsichtsmaßnahmen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Clinically significant cardiovascular effects and fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs. (Fachinformation zu Budesonid und Formoterol, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Vasopressors should not be used in the presence of ergot-type oxytocic drugs, since a severe persistent hypertension may occur. (Fachinformation zu Chloroprocain, Warnhinweise)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Avoid concomitant use of other drugs that are also associated with similar cardiac effects (e.g., amphetamines, other sympathomimetic agents, atropine, amoxapine, scopolamine, antihistamines, other anticholinergic agents, amitriptyline, desipramine, other tricyclic antidepressants). (Fachinformation zu Dronabinol, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

…occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

When LABA are used in fixed-dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone [see Serious Asthma-Related Events with Inhaled Corticosteroid/Long-acting Beta 2 -adrenergic Agonists] . (Fachinformation zu Fluticason und Salmeterol, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

The increased risk of asthma-related death is considered a class effect of the long-acting beta 2 -adrenergic agonists, including formoterol fumarate inhalation solution. (Fachinformation zu Formoterol, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

DO NOT EXCEED RECOMMENDED DOSE Fatalities have been reported in association with excessive use of inhaled products containing sympathomimetic amines and with the home use of nebulizers. (Fachinformation zu Ipratropiumbromid und Salbutamol, Warnhinweise)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

WARNING: ABUSE AND DEPENDENCE CNS stimulants, including cocaine hydrochloride, have a high potential for abuse and dependence. (Fachinformation zu Kokain, Boxed Warning (umrahmter Warnhinweis))

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Do Not Exceed Recommended Dose Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. (Fachinformation zu Levosalbutamol, Warnhinweise und Vorsichtsmaßnahmen)

Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. (Fachinformation zu Levothyroxin und Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

• Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions (6) , Drug Interactions (7.7) , and Overdosage (10) ] . (Fachinformation zu Liothyronin, Boxed Warning (umrahmter Warnhinweis))

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Mepivacaine with epinephrine or other vasopressors should not be used concomitantly with ergot-type oxytocic drugs, because a severe persistent hypertension may occur. (Fachinformation zu Mepivacain, Warnhinweise)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Many patients who received Xyrem during clinical trials in narcolepsy were receiving central nervous system stimulants [see Clinical Trials ( 14 )]. (Fachinformation zu Natriumoxybat, Boxed Warning (umrahmter Warnhinweis))

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Pimozide should not be used in patients taking drugs that may, themselves, cause motor and phonic tics (e.g., pemoline, methylphenidate and amphetamines) until such patients have been withdrawn from these drugs to determine whether or not the drugs, rather than Tourette’s Disorder, are responsible for the tics. (Fachinformation zu Pimozid, Gegenanzeigen)

Epinephrine Because of the potential for Promethazine to reverse epinephrine's vasopressor effect, epinephrine should NOT be used to treat hypotension associated with Promethazine Syrup overdose. (Fachinformation zu Promethazin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Vasopressors and resuscitation equipment should be immediately available in case of a severe reaction to protamine. (Fachinformation zu Protamin, Boxed Warning (umrahmter Warnhinweis))

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Do Not Exceed Recommended Dose Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. (Fachinformation zu Salbutamol, Warnhinweise und Vorsichtsmaßnahmen)

WARNING: ASTHMA-RELATED DEATH Long-acting beta 2 -adrenergic agonists (LABA), such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without inhaled corticosteroids [ICS]) increase the risk of asthma-related death. (Fachinformation zu Salmeterol, Boxed Warning (umrahmter Warnhinweis))

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

If serotonin syndrome occurs, discontinue methamphetamine hydrochloride tablets, USP and the CYP2D6 inhibitor [see Warnings and Precautions 5.8]. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Hypersensitivity Terbutaline sulfate is contraindicated in patients known to be hypersensitive to sympathomimetic amines or any component of this drug product. (Fachinformation zu Terbutalin, Gegenanzeigen)

Hypotension: monitor for signs and symptoms of hypotension, in particular in patients receiving concurrent antihypertensives; Zanaflex should not be used with other α 2 -adrenergic agonists ( 5.1 , 7.7 ) (Fachinformation zu Tizanidin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with other amphetamine products [see Adverse Reactions ( 6 )]. taking monoamine oxidase inhibitors (MAOIs), or within 14 days following discontinuation of treatment with an MAOIs (including MAOIs such as linezolid or intravenous methylene blue), because… (Fachinformation zu Metamfetamin, Gegenanzeigen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

• use of a long-acting beta 2 -adrenergic agonist (LABA), including vilanterol, one of the active ingredients in Umeclidinium and Vilanterol ELLIPTA, without an inhaled corticosteroid (ICS), in patients with asthma [see Warnings and Precautions ( 5.1 )] . (Fachinformation zu Umeclidiniumbromid und Vilanterol, Gegenanzeigen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Acetazolamide decreases urinary excretion of amphetamine and may enhance the magnitude and duration of their effect. (Fachinformation zu Acetazolamid, Arzneimittelwechselwirkungen)

Sympathomimetics, Methylxanthines, Steroids In clinical studies, concurrent administration of aclidinium bromide and other drugs commonly used in the treatment of COPD including sympathomimetics (short-acting beta 2 agonists), methylxanthines, and oral and inhaled steroids showed no increases in adverse drug reactions. (Fachinformation zu Aclidiniumbromid, Arzneimittelwechselwirkungen)

Tricyclic Antidepressants Clinical Impact: May enhance the activity of tricyclic or sympathomimetic agents causing sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs and isoniazid Alogliptin Cytochrome (CYP) P450, CYP-Substrates or Inhibitors Clinical Impact: Insulin Secretagogues and Insulin Insulin and insulin secretagogues… (Fachinformation zu Alogliptin und Metformin, Arzneimittelwechselwirkungen)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Fachinformation zu Alprazolam, Warnhinweise und Vorsichtsmaßnahmen)

Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Fachinformation zu Bortezomib, Warnhinweise und Vorsichtsmaßnahmen)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Brimonidin und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Very rarely, hypotension may be severe such that it may warrant the use of intravenous fluids and/or vasopressors. (Fachinformation zu Candesartan, Warnhinweise und Vorsichtsmaßnahmen)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Fachinformation zu Chlordiazepoxid, Warnhinweise)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Fachinformation zu Chlordiazepoxid und Clidiniumbromid, Warnhinweise)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Fachinformation zu Clonazepam, Warnhinweise)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Fachinformation zu Diazepam, Warnhinweise)

…drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. (Fachinformation zu Dicycloverin, Arzneimittelwechselwirkungen)

Sympathomimetics Epinephrine Can increase the risk of cardiac arrhythmias. (Fachinformation zu Digoxin, Arzneimittelwechselwirkungen)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Fachinformation zu Dikaliumclorazepat, Warnhinweise)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Dorzolamid und Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Drug Interactions Administration of doxapram to patients who are receiving sympathomimetic or monoamine oxidase inhibiting drugs may result in an additive pressor effect (see PRECAUTIONS, General ). (Fachinformation zu Doxapram, Arzneimittelwechselwirkungen)

• Pr e ssor Effect with Concomitant Oxytocic Drugs : Pressor effect of sympathomimetic pressor amines is potentiated (5.1) (Fachinformation zu Ephedrin, Warnhinweise und Vorsichtsmaßnahmen)

Sympathomimetic drugs: Dose adjustment needed (7) (Fachinformation zu Esmolol, Arzneimittelwechselwirkungen)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Fachinformation zu Estazolam, Warnhinweise)

…somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (Fachinformation zu Glimepirid, Arzneimittelwechselwirkungen)

…olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), thyroid hormones, phenytoin, nicotinic acid, and calcium channel blocking drugs. (Fachinformation zu Glipizid, Arzneimittelwechselwirkungen)

In these cases, high-dosage guanfacine was discontinued; concomitant stimulant use was also reported, which may potentially increase hypertensive response upon abrupt discontinuation of guanfacine. (Fachinformation zu Guanfacin, Warnhinweise und Vorsichtsmaßnahmen)

…Insulin Aspart Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin aspart, Arzneimittelwechselwirkungen)

…Insulin Degludec Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin degludec, Arzneimittelwechselwirkungen)

…Effect of LEVEMIR Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin detemir, Arzneimittelwechselwirkungen)

…Glargine-yfgn Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin glargin, Arzneimittelwechselwirkungen)

…Effect of LYUMJEV Drugs: Atypical antipsychotics (e.g., olanzapine and clozapine), corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Insulin lispro, Arzneimittelwechselwirkungen)

Tricyclic Antidepressants Clinical Impact: May enhance the activity of tricyclic or sympathomimetic agents causing sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Sympathomimetics and Vasopressin : Sympathomimetics and vasopressin may enhance the sympathomimetic effects of ketamine [see Drug Interactions ( 7.2 )] . (Fachinformation zu Ketamin, Warnhinweise und Vorsichtsmaßnahmen)

Sympathomimetics Concurrent use may of sympathomimetics and levothyroxine may increase the effects of sympathomimetics or thyroid hormone. (Fachinformation zu Levothyroxin, Arzneimittelwechselwirkungen)

Concurrent administration of vasopressor drugs (for the treatment of hypotension related to obstetric blocks) and ergot-type oxytocic drugs may cause severe, persistent hypertension or cerebrovascular accidents. (Fachinformation zu Lidocain, Arzneimittelwechselwirkungen)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Fachinformation zu Lorazepam, Warnhinweise und Vorsichtsmaßnahmen)

If hypotension does occur during anesthesia, it usually can be controlled by vasopressors. (Fachinformation zu Methyldopa, Arzneimittelwechselwirkungen)

Sympathomimetics Metolazone may decrease arterial responsiveness to norepinephrine, but this diminution is not sufficient to preclude effectiveness of the pressor agent for therapeutic use. (Fachinformation zu Metolazon, Arzneimittelwechselwirkungen)

Drugs and Herbals That May Reduce the Blood-Glucose-Lowering Effect of Nateglinide and Increase Susceptibility to Hyperglycemia Drugs: Thiazides, corticosteroids, thyroid products, sympathomimetics, somatropin, somatostatin analogues (e.g., lanreotide, octreotide), and CYP inducers (e.g., rifampin, phenytoin and St John's Wort). (Fachinformation zu Nateglinid, Arzneimittelwechselwirkungen)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Fachinformation zu Oxazepam, Warnhinweise)

Tricyclic Antidepressants Clinical Impact: May enhance the activity of tricyclic or sympathomimetic agents causing sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Tricyclic Antidepressants Clinical Impact: May enhance the activity of tricyclic or sympathomimetic agents causing sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

…somatropin, protease inhibitors, atypical antipsychotic medications (e.g., olanzapine and clozapine), barbiturates, diazoxide, laxatives, rifampin, thiazides and other diuretics, corticosteroids, phenothiazines, thyroid hormones, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics (e.g., epinephrine, albuterol, terbutaline), and isoniazid. (Fachinformation zu Pioglitazon und Glimepirid, Arzneimittelwechselwirkungen)

Pharmacodynamic Drug-Drug Interactions Adrenergic Agonists: Beta-blockers may antagonize the antihypertensive effects of clonidine, and rebound hypertension may result if clonidine is withdrawn abruptly. (Fachinformation zu Propranolol, Arzneimittelwechselwirkungen)

Tricyclic Antidepressants Clinical Impact: May enhance the activity of tricyclic or sympathomimetic agents causing sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Beta-2-Receptor Stimulants Beta-agonists such as albuterol, terbutaline and isoproterenol may have to be administered in increased dosages when used concomitantly with sotalol. (Fachinformation zu Sotalol, Arzneimittelwechselwirkungen)

The most commonly described clinical features in reports of anaphylaxis were dermatologic symptoms (including urticaria, rash, erythema, flushing and skin eruption); and clinically important hypotension often requiring the use of vasopressors for circulatory support. (Fachinformation zu Sugammadex, Warnhinweise und Vorsichtsmaßnahmen)

Circulatory Shock Circulatory shock with fever, severe hypotension, and confusion requiring intravenous fluid resuscitation and vasopressors has occurred within minutes to hours of re-challenge with trimethoprim-sulfamethoxazole products in patients with history of recent (days to weeks) exposure to sulfamethoxazole and trimethoprim. (Fachinformation zu Sulfamethoxazol und Trimethoprim (Cotrimoxazol), Warnhinweise)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Fachinformation zu Temazepam, Warnhinweise)

If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists. (Fachinformation zu Timolol, Warnhinweise und Vorsichtsmaßnahmen)

Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (Fachinformation zu Tiotropiumbromid, Arzneimittelwechselwirkungen)

Drugs That Increase Catecholamines: Tolcapone did not influence the effect of ephedrine, an indirect sympathomimetic, on hemodynamic parameters or plasma catecholamine levels, either at rest or during exercise. (Fachinformation zu Tolcapon, Arzneimittelwechselwirkungen)

Prescribe the lowest effective dosage; avoid or minimize concomitant use of CNS depressants and other substances associated with abuse, misuse, and addiction (e.g., opioid analgesics, stimulants); and advise patients on the proper disposal of unused drug. (Fachinformation zu Triazolam, Warnhinweise und Vorsichtsmaßnahmen)

Tricyclic Antidepressants Clinical Impact: May enhance the activity of tricyclic or sympathomimetic agents causing sustained increases in the concentration of d-amphetamine in the brain; cardiovascular effects can be potentiated. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

The risk is increased with concomitant use of other serotonergic drugs (including selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, tramadol, meperidine, methadone, lithium, tryptophan, buspirone, amphetamines, and St. (Fachinformation zu Ziprasidon, Warnhinweise und Vorsichtsmaßnahmen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel-blocking drugs, and isoniazid. (Fachinformation zu Acarbose, Arzneimittelwechselwirkungen)

A bronchodilator, such as theophylline or a β2-stimulant, should be made available in advance with instructions concerning its use. (Fachinformation zu Acebutolol, Warnhinweise)

Drug Interactions Careful observation is required when amantadine hydrochloride is administered concurrently with central nervous system stimulants. (Fachinformation zu Amantadin, Arzneimittelwechselwirkungen)

…occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Severe reactions have required intervention with vasopressor agents and supportive measures. (Fachinformation zu Benzonatat, Warnhinweise)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

There are postmarketing reports of hypertension and tachycardia when bromocriptine was co-administered with sympathomimetic drugs (e.g., phenylpropanolamine and isometheptene) in postpartum women. (Fachinformation zu Bromocriptin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

These medications include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Dapagliflozin und Metformin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Empagliflozin und Metformin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Glibenclamid, Arzneimittelwechselwirkungen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Glibenclamid und Metformin, Arzneimittelwechselwirkungen)

These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Glipizid und Metformin, Vorsichtsmaßnahmen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Insulin requirements in diabetes mellitus may be altered in association with the use of methamphetamine and the concomitant dietary regimen. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

ATROVENT HFA has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, oral and inhaled steroids commonly used in the treatment of COPD. (Fachinformation zu Ipratropiumbromid, Arzneimittelwechselwirkungen)

Labetalol has also been reported to produce a false-positive test for amphetamine when screening urine for the presence of drugs using the commercially available assay methods. (Fachinformation zu Labetalol, Arzneimittelwechselwirkungen)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Linagliptin und Metformin, Arzneimittelwechselwirkungen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Metformin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

If a vasopressor is needed, norepinephrine may be used. (Fachinformation zu Perphenazin, Warnhinweise)

These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Pioglitazon und Metformin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

These effects are responsive to discontinuation of DIPRIVAN, intravenous fluid administration, and/or vasopressor therapy. (Fachinformation zu Propofol, Warnhinweise und Vorsichtsmaßnahmen)

In addition, in vitro data indicate that ramelteon does not cause false-positive results for benzodiazepines, opiates, barbiturates, cocaine, cannabinoids, or amphetamines in two standard urine drug screening methods in vitro . (Fachinformation zu Ramelteon, Warnhinweise und Vorsichtsmaßnahmen)

…antipsychotics (e.g., olanzapine and clozapine), calcium channel antagonists, corticosteroids, danazol, diuretics, estrogens, glucagon, isoniazid, niacin, oral contraceptives, phenothiazines, progestogens (e.g., in oral contraceptives), protease inhibitors, somatropin, sympathomimetic agents (e.g., albuterol, epinephrine, terbutaline), and thyroid hormones. (Fachinformation zu Repaglinid, Arzneimittelwechselwirkungen)

These medications include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. (Fachinformation zu Saxagliptin und Metformin, Arzneimittelwechselwirkungen)

Examples: Thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers, and isoniazid. (Fachinformation zu Sitagliptin und Metformin, Arzneimittelwechselwirkungen)

In most cases, patients were using concomitant medications (antidepressants, antipsychotics, stimulants, narcotics) that are thought to lower the seizure threshold. (Fachinformation zu Tiagabin, Warnhinweise)

Insulin requirements in diabetes mellitus may be altered in association with the use of methamphetamine and the concomitant dietary regimen. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

Drug/Laboratory Test Interactions Amphetamines can cause a significant elevation in plasma corticosteroid levels. (Fachinformation zu Metamfetamin, Arzneimittelwechselwirkungen)

…occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (Fachinformation zu Metamfetamin, Warnhinweise und Vorsichtsmaßnahmen)